Alzamend Neuro, Inc. - 8-K Filing

Alzamend Neuro pauses Bipolar Disorder clinical trial following negative FDA feedback and terminates Statement of Work with Massachusetts General Hospital.

SEC EDGAR ·

Tickers: $ALZN

Read the full article at SEC EDGAR

More Regulatory news